Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the invention described herein relates to the use of acetyl L- carnitine for the preparation of a medicine for tbie treatment of neuropathic pain in patients with type 2 diabetes not on insulin treatment.
• Diabetic neuropathy is the most frequent peripheral neuropathy in the western world and includes different forms of neuropathy, among which diabetic polyneuropathy is the most common.
• the anatomico-pathological picture of diabetic neuropathy consists in a focal or diffuse aspecific loss of fibres, with demyelination associated with structural or intraneuronal abnormalities of the connective tissue or of the small vessels.
• diabetic polyneuropathy consist in the presence of lancinating or burning pain accompanied by clinical signs of symmetrical impairment of sensitivity, motility and/ or deep tendon reflexes; these symptoms are predominant in the distal segments of the lower limbs.
• acetyl L-carnitine for the treatment of neuropathic pain in patients with diabetes has failed to take account of the selection of patients on the basis of the type of diabetes and the type of antidiabetic agents taken up to the time of entry into clinical trials.
• US 6,037,3721128 relates to the use of acetyl L-carnitine, isovaleryl L-carnitine and propionyl L-carnitine for increasing IGF-I levels, for the treatment of lateral amyotrophic sclerosis, optic and olfactory nerve neuropathies, trigeminal nerve neuralgia and other pathologies.
• US 6037372 relates to the use of an alkanoyl L-carnitine, including acetyl L-carnitine, for the treatment of diseases mediated by glutamate, such as epilepsy, schizophrenia, chronic fatigue syndrome, lateral amyotrophic sclerosis and other pathologies.
• diseases mediated by glutamate such as epilepsy, schizophrenia, chronic fatigue syndrome, lateral amyotrophic sclerosis and other pathologies.
• acetyl L-carnitine lends itself to use as an effective agent for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.
• acetyl L-carnitine for the treatment of neuropathies is already known. What is still unknown today at the time of filing the present application is that acetyl L- carnitine is useful for treating diabetic neuropathies in patients with type 2 diabetes non on insulin treatment.
• the subject of the present invention is therefore the use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.
• acetyl L-carnitine is any salt of the latter with an acid that does not give rise to unwanted toxic or side effects. These acids are well known to experts in pharmaceutical technology.
• salts are: chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino-ethane sulphonate, magnesium 2-amino-ethane sulphonate, choline tartrate and trichloroacetate .
• EXAMPLE 1 Two double-blind placebo- controlled clinical trials, identical in their experimental design, were conducted in patients with diagnoses of diabetic peripheral neuropathy selected according to the criteria established in the San Antonio, Texas conference ⁇ Diabetes 37: 1000-1004, 1988).
• Acetyl L-carnitine was administered orally at doses of 1.5 g/day and 3.0 g/day for continuously for 52 weeks.
• VAS Visual Analogue Scale
• Two populations of patients with type 2 diabetes were treated, the first of which comprised patients not treated with insulin; this population included the presence of a control group of patients who did not receive the study compound (placebo, Group 1) and who matched up to the same inclusion criteria as the patients treated with acetyl L-carnitine (not on insulin treatment) .
• the second population comprised patients with type 2 diabetes treated with insulin.
• the population included a placebo group (Group 4) matching up to the same inclusion criteria as the patients treated with acetyl L-carnitine (on insulin treatment) .
• Acetyl L-carnitine is a known compound, whose preparation procedure is described in US patents US 4439438 and US 4254053.
• the acetyl L-carnitine can be in any form suitable for oral or parenteral administration in human subjects.
• the compound according to the invention can be marketed as a food supplement or nutritional supplement, or as a therapeutic product on sale either with or without a compulsory doctor's prescription. It has been found that, although the daily dose of the above- mentioned active ingredient to be administered depends on the patient's age, weight and general condition, using professional experience, it is generally advisable to administer, whether as a single dose or in multiple doses, approximately 1.5 to 5 g/day of acetyl L-carnitine, or an equimolar amount of one of its pharmaceutically acceptable salts. The preferred doses are greater than 1.5 g/day and may be as much as the maximum dose advised, thanks to the extremely low toxicity of said active ingredient.
• the medicine according to the present invention can be prepared by mixing the active ingredient (acetyl L-carnitine inner salt or one of its pharmaceutically acceptable salts) with suitable excipients for the formulation of compositions for enteral administration (particularly oral administration) or for parenteral administration (particularly via the intramuscular o intravenous routes) .
• suitable excipients for the formulation of compositions for enteral administration (particularly oral administration) or for parenteral administration (particularly via the intramuscular o intravenous routes) .
• Experts in pharmaceutical technology are familiar with said excipients.
• the pharmaceutically acceptable salts of the above-mentioned active ingredients include all the pharmaceutically acceptable salts which are prepared by addition of an acid to acetyl L-carnitine inner salt, and which do not give rise to unwanted toxic or side effects.
• the formation of salts by addition of an acid is well known in pharmaceutical technology.

Landscapes

• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Emergency Medicine (AREA)
• Diabetes (AREA)
• Neurology (AREA)
• Epidemiology (AREA)
• Obesity (AREA)
• Pain & Pain Management (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Neurosurgery (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Endocrinology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Saccharide Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34965656

Family Applications (1)

Country Status (14)

Families Citing this family (3)

Citations (1)

Family Cites Families (7)

• 2004
  • 2004-07-01 IT IT000327A patent/ITRM20040327A1/it unknown
  • 2004-10-21 US US10/969,217 patent/US20060004095A1/en not_active Abandoned
• 2005
  • 2005-04-05 SI SI200531946T patent/SI1761257T1/sl unknown
  • 2005-04-05 PT PT57303166T patent/PT1761257E/pt unknown
  • 2005-04-05 KR KR1020077000584A patent/KR101176347B1/ko not_active Expired - Fee Related
  • 2005-04-05 PL PL05730316T patent/PL1761257T3/pl unknown
  • 2005-04-05 WO PCT/EP2005/003557 patent/WO2006002698A1/en not_active Ceased
  • 2005-04-05 JP JP2007519628A patent/JP5519907B2/ja not_active Expired - Fee Related
  • 2005-04-05 CA CA2570268A patent/CA2570268C/en not_active Expired - Lifetime
  • 2005-04-05 US US11/570,484 patent/US20070213408A1/en not_active Abandoned
  • 2005-04-05 DK DK05730316T patent/DK1761257T3/en active
  • 2005-04-05 ES ES05730316.6T patent/ES2532497T3/es not_active Expired - Lifetime
  • 2005-04-05 EP EP05730316.6A patent/EP1761257B1/en not_active Expired - Lifetime
  • 2005-04-05 MX MXPA06014907A patent/MXPA06014907A/es not_active Application Discontinuation
• 2015
  • 2015-03-23 CY CY20151100283T patent/CY1116171T1/el unknown

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events